Kytril, Sancuso(granisetron)
Granisetron, Sancuso, Sustol (granisetron) is a small molecule pharmaceutical. Granisetron was first approved as Kytril on 1993-12-29. It has been approved in Europe to treat neoplasms and vomiting.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Granisetron, Sancuso, Sustol (discontinued: Granisetron, Kytril)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Granisetron hydrochloride
Granisetron
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SANCUSO | Cumberland Pharmaceuticals | N-022198 RX | 2008-09-12 | 1 products, RLD, RS |
| SUSTOL | Heron Therapeutics | N-022445 RX | 2016-08-09 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| granisetron | ANDA | 2022-11-15 |
| granisetron hydrochloride | ANDA | 2025-04-24 |
| sancuso | New Drug Application | 2024-11-04 |
| sustol | New Drug Application | 2024-09-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J1626 | Injection, granisetron hydrochloride, 100 mcg |
| J1627 | Injection, granisetron, extended-release, 0.1 mg |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
| S0091 | Granisetron hydrochloride, 1 mg (for circumstances falling under the medicare statute, use q0166) |
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | 5 | 12 | 24 | 14 | 15 | 70 |
| Nausea | D009325 | — | R11.0 | 2 | 9 | 21 | 11 | 13 | 56 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | 2 | 4 | 7 | 4 | 17 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | 5 | 1 | 4 | 15 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | — | 1 | 2 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | 1 | 2 | 4 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | 2 | 1 | 1 | 4 |
| Postoperative pain | D010149 | — | G89.18 | — | 1 | 1 | 1 | 1 | 4 |
| Leukemia | D007938 | — | C95 | — | — | — | 1 | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | 1 | — | 1 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | 1 | 2 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | 1 | — | 1 | 2 |
| Uterine cervical neoplasms | D002583 | — | — | — | — | 1 | — | 1 | 2 |
| Bariatric surgery | D050110 | — | — | — | — | 1 | — | 1 | 2 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | 1 | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | 1 | — | — | 1 |
| Digestive system neoplasms | D004067 | — | — | — | — | 1 | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | — | 1 | — | — | 1 |
| Vasculitis | D014657 | EFO_0006803 | M31 | — | — | 1 | — | — | 1 |
| Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | — | — | 1 | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | — | 2 | — | — | — | 2 |
| Chronic pain | D059350 | — | — | — | 1 | — | — | 1 | 2 |
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
| Mast-cell leukemia | D007946 | — | C94.3 | — | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | — | — | — | 1 |
| Septic shock | D012772 | — | A48.3 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | 1 | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Respiratory aspiration of gastric contents | D063466 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Tissue adhesions | D000267 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tick-borne encephalitis | D004675 | EFO_1001309 | A84 | — | — | — | — | 3 | 3 |
| Encephalitis | D004660 | — | — | — | — | — | — | 3 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 2 | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
| Brenner tumor | D001948 | — | — | — | — | — | — | 1 | 1 |
| Endometrioid carcinoma | D018269 | — | — | — | — | — | — | 1 | 1 |
| Mucinous cystadenocarcinoma | D018282 | — | — | — | — | — | — | 1 | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | — | — | — | — | 1 | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Granisetron |
| INN | granisetron |
| Description | 1-Methyl-N-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1H-indazole-3-carboxamide is a member of indazoles and an aromatic amide. |
| Classification | Small molecule |
| Drug class | serotonin 5-HT3 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2 |
Identifiers
| PDB | — |
| CAS-ID | 107007-99-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL289469 |
| ChEBI ID | — |
| PubChem CID | 3510 |
| DrugBank | DB00889 |
| UNII ID | WZG3J2MCOL (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Sancuso – Cumberland Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sustol – Heron Therapeutics /de/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Granisetron
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,523 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,452 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use